[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

TR200502508T2 - IL-18 İnhibitörlerinin kullanımı. - Google Patents

IL-18 İnhibitörlerinin kullanımı.

Info

Publication number
TR200502508T2
TR200502508T2 TR2005/02508T TR200502508T TR200502508T2 TR 200502508 T2 TR200502508 T2 TR 200502508T2 TR 2005/02508 T TR2005/02508 T TR 2005/02508T TR 200502508 T TR200502508 T TR 200502508T TR 200502508 T2 TR200502508 T2 TR 200502508T2
Authority
TR
Turkey
Prior art keywords
inhibitors
arthritis
medicament
prevention
preparation
Prior art date
Application number
TR2005/02508T
Other languages
English (en)
Inventor
Chvatchko Yolande
Dinarello Charles
Plater-Zyberk Christine
Van Deventer Santer
Rubinstein Menachem
Novick Daniela
Kim Soo-Hyun
Original Assignee
Applied Research Systems Ar� Holding N.V.
Yeda Research And Developmbnt Company Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems Ar� Holding N.V., Yeda Research And Developmbnt Company Ltd. filed Critical Applied Research Systems Ar� Holding N.V.
Publication of TR200502508T2 publication Critical patent/TR200502508T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Addiction (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Buluş, artritin, özellikle römatoid artritın tedavi ve/veya önlenmesi için bir ilacın hazırlanmasında IL-18 inhıbitörlerinin kullanımı ile ilgilidir.
TR2005/02508T 2000-02-21 2001-02-20 IL-18 İnhibitörlerinin kullanımı. TR200502508T2 (tr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP00103590 2000-02-21
EP00103597 2000-02-21
EP00121651 2000-10-04
EP00125633 2000-11-23

Publications (1)

Publication Number Publication Date
TR200502508T2 true TR200502508T2 (tr) 2007-04-24

Family

ID=27439934

Family Applications (2)

Application Number Title Priority Date Filing Date
TR2005/02508T TR200502508T2 (tr) 2000-02-21 2001-02-20 IL-18 İnhibitörlerinin kullanımı.
TR2002/02030T TR200202030T2 (tr) 2000-02-21 2001-02-20 IL-18 inhibitörlerinin kullanımı.

Family Applications After (1)

Application Number Title Priority Date Filing Date
TR2002/02030T TR200202030T2 (tr) 2000-02-21 2001-02-20 IL-18 inhibitörlerinin kullanımı.

Country Status (31)

Country Link
US (1) US20030157094A1 (tr)
EP (1) EP1257292B1 (tr)
JP (1) JP4744763B2 (tr)
KR (3) KR20070057282A (tr)
CN (1) CN1322897C (tr)
AT (1) ATE506959T1 (tr)
AU (2) AU2001240636B8 (tr)
BG (1) BG66134B1 (tr)
BR (1) BR0108514A (tr)
CA (2) CA2399298C (tr)
CY (1) CY1111687T1 (tr)
CZ (1) CZ304485B6 (tr)
DE (1) DE60144514D1 (tr)
DK (1) DK1257292T3 (tr)
EA (1) EA005583B1 (tr)
EE (1) EE05423B1 (tr)
HK (1) HK1051965A1 (tr)
HR (1) HRP20020652A2 (tr)
HU (1) HU227752B1 (tr)
IL (2) IL151388A0 (tr)
ME (1) ME00546B (tr)
MX (1) MXPA02008079A (tr)
NO (1) NO331971B1 (tr)
NZ (3) NZ546294A (tr)
PL (1) PL206549B1 (tr)
PT (1) PT1257292E (tr)
RS (1) RS51737B (tr)
SI (1) SI1257292T1 (tr)
SK (1) SK288032B6 (tr)
TR (2) TR200502508T2 (tr)
WO (1) WO2001062285A1 (tr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001236807A1 (en) * 2000-02-10 2001-08-20 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
KR20070057282A (ko) * 2000-02-21 2007-06-04 어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. Ｉｌ-18 저해물질의 용도
US6894155B2 (en) 2000-10-11 2005-05-17 Viron Therapeutics Nucleic acid molecules and polypeptides for immune modulation
US7718368B2 (en) 2000-12-04 2010-05-18 Viron Therapeutics Inc. Immunomodulatory protein and useful embodiments thereof
BR0210904A (pt) * 2001-05-16 2005-08-16 Yeda Res & Dev Uso de inibidores de il-18 para o tratamento ou prevenção de sepse
MXPA04002565A (es) * 2001-11-30 2004-05-31 Pfizer Prod Inc Combinacion de un inhibidor de il-1/18 con un inhibidor de tnf para el tratamiento de inflamacion.
WO2004064713A2 (en) * 2003-01-20 2004-08-05 Vib Vzw The use of yop preoteins or rho gtpase inhibitors as caspase-1 inhibitors
JP4134166B2 (ja) * 2003-04-30 2008-08-13 独立行政法人科学技術振興機構 ヒト抗ヒトインターロイキン−１８抗体およびその断片、並びにそれらの利用方法
CA2545733A1 (en) * 2003-11-10 2005-05-26 Vertex Pharmaceuticals Incorporated Methods for monitoring il-18
US7968684B2 (en) * 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
NZ552908A (en) 2004-06-30 2009-11-27 Atsuo Sekiyama Indicator agent for noninflammatory stress response and use thereof
DK1808446T3 (da) * 2004-07-16 2012-05-14 Atsuo Sekiyama IL-18-receptor-antagonist og farmaceutisk sammensætning indeholdende antagonisten
SI2267024T1 (sl) 2005-06-03 2012-09-28 Ares Trading Sa Proizvodnja rekombinantnega IL-18 vezavnega proteina
ES2375831T3 (es) 2005-06-10 2012-03-06 Ares Trading S.A. Procedimiento para la purificación de prote�?nas de unión a il-18.
EP1746167A1 (en) * 2005-07-20 2007-01-24 Apoxis SA Method for the identification of compounds susceptible to inhibit inflammation
ES2514495T3 (es) 2006-05-25 2014-10-28 Glaxo Group Limited Anticuerpos humanizados modificados anti-interleucina-18
US8440195B2 (en) * 2010-11-12 2013-05-14 National University Corporation Chiba University Inhibition of CD69 for treatment of inflammatory conditions
GB201213968D0 (en) * 2012-08-06 2012-09-19 Isis Innovation Prevention and treatment of osteoarthritis
KR102512797B1 (ko) * 2013-09-05 2023-03-22 에이비2 바이오 에스에이 염증성 질환에서 il-18 결합 단백질(ｉｌ-18ｂｐ)
CN107660150B (zh) 2015-03-05 2023-10-24 Ab2生物股份有限公司 Il-18结合蛋白(il-18bp)和抗体在炎性疾病中
CN106109497A (zh) * 2016-07-25 2016-11-16 深圳爱生再生医学科技有限公司 治疗肝硬化的干细胞制剂
CN106834449B (zh) * 2017-01-10 2019-04-30 东南大学 与原发性胆汁性胆管炎关联的白细胞介素21受体及其应用
CN112236453A (zh) * 2018-06-14 2021-01-15 波尔多大学 使用白细胞介素-1抑制剂治疗胎盘慢性组织细胞绒毛间质炎
JPWO2023286694A1 (tr) 2021-07-13 2023-01-19
CN117647645B (zh) * 2024-01-29 2024-04-12 中国人民解放军总医院第一医学中心 Lbp、atf6、m-csfr联用在制备诊断自身免疫性肝病产品中的应用及试剂盒

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985863A (en) * 1996-09-12 1999-11-16 Vertex Pharmaceuticals, Inc. Compositions and methods for decreasing IGIF and IFN-γ production by administering an ICE inhibitor
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5744451A (en) * 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
EP0936923B1 (en) * 1996-11-15 2003-12-17 Kennedy Institute Of Rheumatology SUPPRESSION OF TNFalpha AND IL-12 IN THERAPY
US7141393B2 (en) * 1996-12-26 2006-11-28 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18-receptor proteins
JP4026923B2 (ja) * 1997-03-12 2007-12-26 株式会社林原生物化学研究所 ポリペプチド
US6087116A (en) * 1997-03-12 2000-07-11 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18 (IL-18) receptor polypeptides and their uses
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
CA2276216A1 (en) * 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
EP1110969A4 (en) * 1998-09-01 2002-01-09 Hayashibara Biochem Lab INTERLEUKIN 18 BINDING PROTEIN
AR022952A1 (es) * 1999-03-19 2002-09-04 Smithkline Beecham Corp ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL
AU2001236807A1 (en) * 2000-02-10 2001-08-20 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
KR20070057282A (ko) * 2000-02-21 2007-06-04 어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. Ｉｌ-18 저해물질의 용도
WO2002032374A2 (en) * 2000-10-18 2002-04-25 Immunex Corporation Methods for treating il-18 mediated disorders

Also Published As

Publication number Publication date
AU4063601A (en) 2001-09-03
CA2399298C (en) 2014-04-15
NO331971B1 (no) 2012-05-14
HRP20020652A2 (en) 2004-12-31
DK1257292T3 (da) 2011-07-18
KR20070087256A (ko) 2007-08-27
KR20020086540A (ko) 2002-11-18
YU60402A (sh) 2005-09-19
NZ546294A (en) 2008-02-29
EE200200463A (et) 2003-12-15
CZ304485B6 (cs) 2014-05-28
PL357554A1 (en) 2004-07-26
AU2001240636B2 (en) 2005-10-13
BR0108514A (pt) 2002-12-17
SK12082002A3 (sk) 2003-05-02
BG107018A (bg) 2003-09-30
JP2003523403A (ja) 2003-08-05
CN1322897C (zh) 2007-06-27
KR20070057282A (ko) 2007-06-04
DE60144514D1 (de) 2011-06-09
HUP0300061A3 (en) 2005-09-28
RS51737B (sr) 2011-10-31
HU227752B1 (en) 2012-02-28
US20030157094A1 (en) 2003-08-21
CN1404400A (zh) 2003-03-19
CA2683009A1 (en) 2001-08-30
BG66134B1 (bg) 2011-06-30
TR200202030T2 (tr) 2003-01-21
EE05423B1 (et) 2011-06-15
CY1111687T1 (el) 2015-10-07
IL151388A0 (en) 2003-04-10
EA005583B1 (ru) 2005-04-28
EA200200890A1 (ru) 2003-02-27
SK288032B6 (sk) 2012-12-03
NO20023962L (no) 2002-08-20
EP1257292A1 (en) 2002-11-20
IL151388A (en) 2009-09-01
EP1257292B1 (en) 2011-04-27
AU2001240636B8 (en) 2005-11-03
ME00546B (me) 2011-10-10
JP4744763B2 (ja) 2011-08-10
NZ535299A (en) 2006-06-30
HUP0300061A2 (hu) 2003-04-28
CZ20022843A3 (cs) 2003-02-12
HK1051965A1 (en) 2003-08-29
PT1257292E (pt) 2011-07-05
CA2399298A1 (en) 2001-08-30
WO2001062285A1 (en) 2001-08-30
SI1257292T1 (sl) 2011-08-31
CA2683009C (en) 2014-09-23
ATE506959T1 (de) 2011-05-15
NO20023962D0 (no) 2002-08-20
MXPA02008079A (es) 2003-02-27
NZ520122A (en) 2005-04-29
PL206549B1 (pl) 2010-08-31

Similar Documents

Publication Publication Date Title
TR200502508T2 (tr) IL-18 İnhibitörlerinin kullanımı.
MY135721A (en) Amidino compounds useful as nitric oxide synthase inhibitors
TR200401264T4 (tr) CB1-reseptör-antagonistiyle-sibütramin birleşimi, bunları içeren farmasötik-bileşimler ve obezite tedavisinde kullanımları.
TR200202194T2 (tr) Poliglütamik asit-kamptotesin birleşikleri ve hazırlama yöntemleri
NO20031672D0 (no) Aza- og polyaza-naftalenylkarboksamider for anvendelse som HIV-integraseinhibitorer
HUP0301577A3 (en) Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors, pharmaceutical compositions containing them and their use
TR200002759T2 (tr) Bacak uyuşması sendromunun tedavisinde kabergolin kullanımı.
CY1110385T1 (el) Χρηση αναστολεων της il-18 για τη θεραπεια και/ή προληψη της αθηροσκληρωσης
MY137620A (en) Therapeutic treatment
FI20000635A0 (fi) COMT-inhibiittoreiden käyttö analgeettina
EE05534B1 (et) IL-18 inhibiitorite kasutamine ravimi valmistamiseks kardiomopaatia raviks ja/v?i ennetamiseks
TR200302134T4 (tr) 2-metil-tiazolidin-2,4-dikarboksilik asit ve/veya bunun fizyolojik olarak uygun tuzlarının anti-kanser ajanları olarak kullanımı.
NZ525774A (en) Use of SARP-1 for the treatment and/or prevention of scleroderma
GR20010100602A (el) Ασπαρτικο παραγωγο της αμλοδιπινης.
BR0012675A (pt) Uso de inibidores de il-18
CY1108053T1 (el) Ενωση της κυαμεμαζινης και ενος ατυπου νευροληπτικου
EP1303300A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANDIDIASIS
TR200002939T2 (tr) Paroksetin maleat
CY1108980T1 (el) Χρηση πολυσουλφωμενων κυκλοδεξτρινων για τη θεραπεια της αρθριτιδας
PT1212119E (pt) Utilizacao de ciamemazina no tratamento do desmame subito de benzodiazepinas
HRP20040071B1 (hr) Upotreba il-18 inhibitora u poremeä†ajima preosjetljivosti
TR200502061T2 (tr) IL-18 inhibitörlerinin kullanımı.
MXPA04000418A (es) Tratamiento de dolor cronico con 3-heterocicloxi- y -cicloalquiloxi-3-fenilpropanaminas.
MD2228G2 (ro) Utilizarea derivaţiilor izotiouronici în tratamentul şi profilaxia atoniei intestinale
MD2066G2 (ro) Remediu antihipertensiv